Navigation Links
Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
Date:10/2/2007

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Didier Barret to the position of President, EMEA (Europe, Middle East and Africa) following the completion of Mylan's acquisition of Merck's Generics Group today.

At Merck Generics, M. Barret most recently served as Region Director, EMEA, reporting to the CEO. He was promoted to that position in 2004 following his role as Area Director for Southern Europe, where he was responsible for France, Belgium, Italy, Spain and Portugal. He established Merck Generics' first operations in France in 1995, growing the business to exceed euro 341 million in sales by 2006. Prior to this, M. Barret held several positions within Merck's branded division, including sales and marketing in the UK and France.

Mylan Vice Chairman and CEO Robert J. Coury commented: "We are very pleased to welcome Didier to the senior leadership team at Mylan. He is a phenomenal operator and leader, having created Merck Generic's business in France literally from nothing to becoming the strong and growing business it is today. Under his leadership of the EMEA region since 2004, growth from operations in these territories has been extremely impressive, at around 12% annual compound growth. As we take our place as a global leader in the generics and specialty pharmaceutical industry, Didier will play a key role in ensuring that we maximize our many opportunities for growth and success moving forward in the EMEA region."

M. Barret said: "I am very excited to be part of the new Mylan. There is a real cultural fit between our organizations and the new management team under Robert is very much operating with a unified vision. Together, our combined company is truly a world leader in our industry, with the depth and scale in terms of product portfolio and pipeline, as well as manufacturing and R&D, to provide our customers, and ultimately patients, with the best quality products and service available. I look forward to being a part of Mylan's future success. I also want to take the opportunity to thank my teams in EMEA for their hard work and the contributions each has made to the success of our business to date and for their commitment to making the new Mylan even more successful in the future."

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and Diversified opportunities in the respiratory and allergy therapeutic areas.

With manufacturing, packaging, distribution and marketing capabilities, Mylan EMEA holds leading positions in several fast-growing markets throughout Europe including France, Germany, United Kingdom, Italy, Spain, Austria, Greece, Ireland, Belgium, Netherlands, Portugal, Scandinavia, as well as South Africa and Morocco.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology: